In vitro and ex vivo toxicological testing of sildenafil-loaded solid lipid nanoparticles

Inhalation Toxicology

Volumn 25, Issue 9, 2013, Pages 536-543

  Paranjpe, M ^a   Neuhaus, V ^b   Finke, J H ^a   Richter, C ^a   Gothsch, T ^a   Kwade, A ^a   Buttgenbach S ^a   Braun, A ^b   Muller Goymann C C ^a  

^a TECHNICAL UNIVERSITY OF BRAUNSCHWEIG   (Germany)

^b FRAUNHOFER INSTITUTE FOR TOXICOLOGY AND EXPERIMENTAL MEDICINE   (Germany)

Author keywords

Lung heart toxicity; Microchannel homogenization; Sildenafil; Solid lipid nanoparticles

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; SILDENAFIL; SOLID LIPID NANOPARTICLE;

ANIMAL CELL; ARTICLE; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; EX VIVO STUDY; HUMAN; HUMAN CELL; LD 50; LUNG ALVEOLUS EPITHELIUM; LUNG SLICE; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PULMONARY HYPERTENSION;

EID: 84881473184     PISSN: 08958378     EISSN: 10917691     Source Type: Journal    
DOI: 10.3109/08958378.2013.810315     Document Type: Article

References (33)

1. Antoniu SA. (2006). Sildenafil for pulmonary arterial hypertension: when blue turns into white. Expert Opin Pharmacother 7:1801-10.
2. Arab Tehrany E, Kahn CJ, Baravian C, et al. (2012). Elaboration and characterization of nanoliposome made of soya; rapeseed and salmon lecithins: application to cell culture. Colloid Surf B: Biointerfaces 95: 75-81.
3. Azarmi S, Roa WH, Lobenberg R. (2008). Targeted delivery of nanoparticles for the treatment of lung diseases: clinical developments in drug delivery nanotechnology. Adv Drug Deliv Rev 60:863-75.
4. Badesch DB. (2010). Pulmonary arterial hypertension baseline characteristics from the REVEAL Registry. Chest 137:376.
5. Beck-Broichsitter M, Gauss J, Packhaeuser CB, et al. (2009). Pulmonary drug delivery with aerosolizable nanoparticles in an ex vivo lung model. Int J Pharm 367:169-78.
6. Beck-Broichsitter M, Kleimann P, Gessler T, et al. (2012). Nebulization performance of biodegradable sildenafil-loaded nanoparticles using the Aeroneb® Pro: formulation aspects and nanoparticle stability to nebulization. Int J Pharm 422:398-408.
7. Bussek A, Schmidt M, Bauriedl J, et al. (2012). Cardiac tissue slices with prolonged survival for in vitro drug safety screening. J Pharmacol Toxicol Methods 66:145-51.
8. Bussek A, Wettwer E, Christ T, et al. (2009). Tissue slices from adult mammalian hearts as a model for pharmacological drug testing. Cell Physiol Biochem 24:527-36.
9. Dupuis J, Hoeper MM. (2008). Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J 31:407-15.
10. Finke J, Schur J, Richter C, et al. (2012). The influence of customized geometries and process parameters on nanoemulsion and solid lipid nanoparticle production in microsystems. Chem Eng J 209: 126-37.
11. Galie N, Manes A, Branzi A. (2003). Prostanoids for pulmonary arterial hypertension. Am J Respir Med 2:123-37.
12. Goris K, Uhlenbruck S, Schwegmann-Wessels C, et al. (2009). Differential sensitivity of differentiated epithelial cells to respiratory viruses reveals different viral strategies of host infection. J Virol 83: 1962-68.
13. Harms M, Mueller-Goymann CC. (2011). Solid lipid nanoparticles for drug delivery (invited review). J Drug Deliv Sci Technol 21:89-99.
14. Huddleston AJ, Knodoerer CA, Morris JL, Ebenroth ES. (2009). Sildenafil for treatment of pulmonary hypertension in pediatric patients. Pediatr Cardiol 30:871-82.
15. 2 nanoparticles for cardiac tissue engineering applications. Nanotoxicology 5:372-80.
16. Jung S-Y, Seo Y-G, Kim GK, et al. (2011). Comparison of the solubility and pharmacokinetics of sildenafil salts. Arch Pharm Res 34:451-4.
17. Kaneko MR, Coppen S. (2012). Histological validation of heart slices as a model in cardiac research. J Cell Sci Ther 3:126. doi: 10.4172/2157-7013. 1000126.
18. Kohler M, Gothsch T, Finke JH, et al. (2011). Effect of microchannel geometry on high-pressure dispersion and emulsification. Chem Eng Technol 34:335-43.
19. Labiris NR, Dolovich MB. (2003). Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 56:588-99.
20. Melnikov P, Corbi PP, Cuin A, et al. (2003). Physicochemical properties of sildenafil citrate (Viagra) and sildenafil base. J Pharm Sci 92: 2140-3.
21. Mosmann T (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63.
22. Muller RH, Mader K, Gohla S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm 50:161-77.
23. Nanjwade BK, Adichwal SA, Gaikwad KR, et al. (2011). Pulmonary drug delivery: novel pharmaceutical technologies breathe new life into the lungs. PDA J Pharm Sci Technol 65:513-34.
24. Nassimi M, Schleh C, Lauenstein HD, et al. (2009). Low cytotoxicity of solid lipid nanoparticles in in vitro and ex vivo lung models. Inhal Toxicol 21:104-9.
25. Nassimi M, Schleh C, Lauenstein HD, et al. (2010). A toxicological evaluation of inhaled solid lipid nanoparticles used as a potential drug delivery system for the lung. Eur J Pharm Biopharm 75: 107-16.
26. Nishiyama T, Mishima K, Ide F, et al. (2007). Functional analysis of an established mouse vascular endothelial cell line. J Vasc Res 44: 138-48.
27. Oberdorster G, Stone V, Donaldson K. (2007). Toxicology of nanoparticles: a historical perspective. Nanotoxicology 1:2-25.
28. Rang HP, Dale MM, Ritter JM, Flower RJ. (2007). Pharmacology. 6th ed. New York: Churchill Livingstone. xiii, 829
29. Revatio®, Revatio website source, Roteliste-Fachinformation, Pfizer Deutschland GmbH, Berlin, Germany. Roggen EL, Soni NK, Verheyen GR. (2006). Respiratory immunotoxi-city: an in vitro assessment. Toxicol In Vitro 20:1249-64.
30. Sakagami M. (2006). In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv Drug Deliv Rev 58:1030-60.
31. Scherließ R. (2011). The MTT assay as tool to evaluate and compare excipient toxicity in vitro on respiratory epithelial cells. Int J Pharm 411:98-105.
32. Sung JC, Pulliam BL, Edwards DA. (2007). Nanoparticles for drug delivery to the lungs. Trends Biotechnol 25:563-70
33. Viagra®, Viagra website source, Roteliste-Fachinformation, Pfizer Deutschland GmbH, Berlin, Germany.